HAS Refuses Early Access to Lecanemab in France: What It Means for Tau-Directed Innovation
On September 4, 2025, the Haute Autorité de Santé (HAS) issued Decision n°2025.0204/DC/SEM, refusing to grant early access (accès précoce) to Lecanemab (Leqembi) in France. The decision applies to the treatment of adult patients with mild cognitive impairment or mild dementia due to early Alzheimer’s disease, non-carriers or heterozygous for the ApoE ε4 allele, with confirmed amyloid pathology. At Glyx Therapeutics, we follow this development closely, as it underscores the scientific and clinical questions that continue to shape the tauopathy and Alzheimer’s treatment landscape.
